Mutations in the gene coding for the putative kinase LRRK2 represent some of the most prevalent genetic factors yet linked to Parkinson’s disease, but how these alterations lead to PD-related ...
Mutations in the gene coding for the putative kinase LRRK2 represent
some of the most prevalent genetic factors yet linked to Parkinson’s
disease, but how these alterations lead to PD-related ...
Mutations in the gene coding for the putative kinase LRRK2 represent some of the most prevalent genetic factors yet linked to Parkinson's disease, but how these alterations lead to PD-related ...
Mutations in the gene coding for the putative kinase LRRK2 represent some of the most prevalent genetic factors yet linked to Parkinson’s disease, but tools for studying LRRK2 are limited. In ...
We've sent out LRRK2 antibodies to over 160 labs, and more than half have submitted their data to MJFF so far. Our summary, posted on the LRRK2 antibody discussion page, points out the strengths and ...
The
Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal
Dementias (AFTD) have announced funding opportunities for research on frontotemporal dementias. The ...
The European Patent Office (EPO) has given Amarantus Therapeutics a Notice of Allowance on mesencephalic astrocyte-derived neurotrophic factor (MANF), which is in preclinical development. According ...
The National Institute of Neurological Disorders and Stroke (NINDS) wants to know what researchers think about tool and resource development needs in the neuroscience and neurology fields. ...